Compare CEPU & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CEPU | FTRE |
|---|---|---|
| Founded | 1989 | 1996 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Medical Specialities |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.5B |
| IPO Year | 2018 | N/A |
| Metric | CEPU | FTRE |
|---|---|---|
| Price | $17.23 | $16.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 10 |
| Target Price | ★ $17.50 | $15.50 |
| AVG Volume (30 Days) | 271.8K | ★ 1.2M |
| Earning Date | 03-10-2026 | 03-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | $607,552,200.00 | ★ $2,759,900,000.00 |
| Revenue This Year | $16.07 | $3.21 |
| Revenue Next Year | $15.36 | $0.25 |
| P/E Ratio | $13.08 | ★ N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $7.43 | $3.97 |
| 52 Week High | $18.50 | $18.82 |
| Indicator | CEPU | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 58.89 | 53.69 |
| Support Level | $14.77 | $15.37 |
| Resistance Level | $15.88 | $17.81 |
| Average True Range (ATR) | 0.85 | 1.15 |
| MACD | -0.01 | -0.19 |
| Stochastic Oscillator | 67.19 | 48.18 |
Central Puerto SA is a power generation company. It is mainly engaged in electric power generation and commercialization. The company is also involved in the natural gas distribution public sector service in the Cuyo and Centro regions in Argentina. The Group has four reporting segments which includes electric power generation from conventional sources, electric power generation from renewable sources, natural gas transport and distribution, and forest activity.. The company derives maximum revenue from Electric Power Generation from conventional sources segment.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.